Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Genistein - Humanetics Corporation

Drug Profile

Genistein - Humanetics Corporation

Alternative Names: BIO-300

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Armed Forces Radiobiology Research Institute; National Institutes of Health (USA)
  • Developer Armed Forces Radiobiology Research Institute; Henry Ford Health System; Humanetics Corporation
  • Class Antineoplastics; Chemosensitisers; Isoflavones; Osteoporosis therapies; Phytotherapies; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Haematopoietic cell growth factor stimulants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Radiation injuries
  • Phase I Acute radiation syndrome

Most Recent Events

  • 30 Oct 2019 Genistein is still in clinical trials for Acute radiation syndrome(Prevention, In volunteers) in USA (PO, Capsule)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Acute-radiation-syndrome(Prevention, In volunteers) in USA (PO, Capsule)
  • 02 Oct 2019 Humanetics Corporation enters into a research agreement with the US Department of Defense (DoD) for development of BIO 301 for prevention of Radiation injuires and acute radiation syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top